Table 2.

Recurrence free and overall survival rates

	Imatinib group (n=16)	Control group (n=26)	p-value
Recurrence free survival			0.012
1 year	100%	92% (95% CI: 73–98%)
3 years	90% (95% CI: 47–99%)	53% (95% CI: 31–71%)
5 years	77% (95% CI: 34–94%)	36% (95% CI: 14–59%)
Median	–	58 mths (95% CI: 28–88 mths)
Overall survival			0.021
1 year	100%	96% (95% CI: 75–99%)
3 years	91% (95% CI: 51–99%)	77% (95% CI: 48–91%)
5 years	68% (95% CI: 38–88%)	39% (95% CI: 13–65%)
Median	–	59 mths (95% CI: 57–60 mths)

CI = confidence interval